Compared with placebo, significant improvement in survival and cardiovascular hospitalization was not observed with anselamimab in the overall patient population. Topline data were announced from a ...

A drug that AstraZeneca singled out as one of its key potential revenue growth drivers in the next decade has failed a pivotal study in light chain amyloidosis, a rare disease with few treatment ...

High-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) phase III clinical programme showed that anselamimab, a light chain depleter antibody, did not achieve statistical ...

AstraZeneca said its amyloidosis treatment anselamimab failed to reach its primary goal in a final-stage trial. The British-Swedish pharmaceutical company said Wednesday that the phase III of its ...

AstraZeneca’s (NYSE:AZN) rare disease division, Alexion, announced that its experimental treatment anselamimab did not achieve the primary objective in a significant late-stage study targeting ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in a phase 3 trial, although the drugmaker thinks it has seen signs of ...

(Reuters) -AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare condition that causes a buildup of protein deposits in the body, ...

Investing.com -- AstraZeneca’s (ST:AZN) rare disease unit Alexion (NASDAQ:ALXN) said its experimental drug anselamimab failed to meet the main goal in a major late-stage trial for patients with a ...

Akero Therapeutics Inc. (NASDAQ:AKRO) is one of the best mid cap pharma stocks to buy. On July 16, AstraZeneca announced that its amyloidosis treatment, called anselamimab, failed to meet its primary ...